Mumbai February 10, 2013:- After the US Food and Drug Administration (USFDA) raised concerns over Ranbaxy’s largest drug ingredient plant at Toansa, many questions regarding the GMP compliance have come up. The company is making every attempt to investigate these issues and aims at resolving them.
During the company’s internal investigations, certain preliminary findings have called attention. These findings point towards a possibility that some of the good manufacturing practice (GMP) violations that the FDA inspectors observed at the Toansa plant could have been framed by some dissatisfied employees. This needs further investigations before concluding anything. – GMP
